Karin J Bosma, Monica Ghosh, Spencer R Andrei, Lin Zhong, Jennifer C Dunn, Valerie F Ricciardi, Juliann B Burkett, Antonis K Hatzopoulos, Derek S Damron, Maureen Gannon
Article in Physiological reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 4 institutions in 1 country.
Karin J BosmaDepartment of Veterans Affairs Tennessee Valley Authority, Nashville, Tennessee, USA.
Monica GhoshDepartment of Biological Sciences, School of Biomedical Sciences, Kent State University, Kent, Ohio, USA.
Spencer R AndreiDepartment of Veterans Affairs Tennessee Valley Authority, Nashville, Tennessee, USA.
Lin ZhongDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jennifer C DunnDepartment of Veterans Affairs Tennessee Valley Authority, Nashville, Tennessee, USA.
Valerie F RicciardiDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Juliann B BurkettDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA.
Antonis K HatzopoulosDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Derek S DamronDepartment of Biological Sciences, School of Biomedical Sciences, Kent State University, Kent, Ohio, USA.
Maureen GannonDepartment of Veterans Affairs Tennessee Valley Authority, Nashville, Tennessee, USA.ORCID 0000-0003-3287-8101
Tennessee Valley Authority · USKent State University · USVanderbilt University · USVanderbilt University Medical Center · US
Funding
MULTIDISCIPLINARY TRAINING IN MOLECULAR ENDOCRINOLOGYT32DK007563 · NIDDK · VANDERBILT UNIVERSITY · PI Richard M O'Brien · 1988 to 2026
$15.9M
Integrated Biological Systems Training in OncologyT32CA119925 · NCI · VANDERBILT UNIVERSITY · PI Vivian Gama, William Patrick Tansey · 2008 to 2026
$7.6M
Manipulating islet GPCR activity to promote beta cell proliferation and survivalR01DK120626 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GANNON, MAUREEN A · 2019 to 2022
$1.7M
Functional heterogeneity of cardiac reparative cells after injuryR01HL138519 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HATZOPOULOS, ANTONIS · 2017 to 2020
$1.6M
Pathways regulating adult pancreatic beta cell replicationI01BX003744 · VA · VETERANS HEALTH ADMINISTRATION · PI GANNON, MAUREEN A · 2017 to 2020
–
Modulating prostaglandin E2 receptor activity to improve pancreatic islet functionI01BX005399 · VA · VETERANS HEALTH ADMINISTRATION · PI GANNON, MAUREEN A · 2022 to 2025
Type 2 diabetes (T2D) affects >30 million Americans and nearly 70% of individuals with T2D will die from cardiovascular disease (CVD). Circulating levels of the inflammatory signaling lipid, prostaglandin E
Indexed as
Diabetes Mellitus, Type 2HyperglycemiaAnimalsDinoprostoneHumansMiceMyocytes, CardiacReceptors, Prostaglandin E, EP3 SubtypeReceptors, Prostaglandin E, EP4 SubtypeDinoprostoneReceptors, Prostaglandin E, EP3 SubtypeReceptors, Prostaglandin E, EP4 Subtypecontractilitydiabetic cardiomyopathyejection fractionprostaglandin receptorType 2 diabetes
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacological modulation of prostaglandin E · full record | OpenQuestion